Latest News | Cipla Inks Licensing Pact with Novartis for Diabetes Drug
Get latest articles and stories on Latest News at LatestLY. Drug major Cipla on Monday said it has inked a licensing pact with Novartis Pharma AG to manufacture and market Galvus range, used in the treatment of type 2 diabetes, from January 1, 2026.
New Delhi, Apr 10 (PTI) Drug major Cipla on Monday said it has inked a licensing pact with Novartis Pharma AG to manufacture and market Galvus range, used in the treatment of type 2 diabetes, from January 1, 2026.
The Mumbai-based company has signed a perpetual license agreement with Novartis Pharma AG (Switzerland) to manufacture and market Galvus and Galvus combination brands, it said in a regulatory filing.
Also Read | EV Sale: Electric Two-Wheeler Sales in India Rise Over Two-and-Half Fold to 8,46,976 Units in 2022-23.
"This deal is expected to further bolster Cipla's position in India as one of the top players in the diabetes category," it added.
The agreement is subject to satisfaction of certain conditions precedent, the drug firm said.
Galvus is one of the leading brands in the Dipeptidyl Peptidase-4 (DPP4) space and amongst the prominent brands in the oral diabetic medication category, the drug firm stated.
On Monday, shares of Cipla ended 1.02 per cent up at Rs 901.85 apiece on the BSE.
(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)